BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21944671)

  • 21. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
    Osonoi T; Saito M; Mochizuki K; Fukaya N; Muramatsu T; Inoue S; Fuchigami M; Goda T
    Metabolism; 2010 Dec; 59(12):1816-22. PubMed ID: 20667563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
    Shibata E; Aoki K; Tajima K; Taguri M; Terauchi Y
    Expert Opin Pharmacother; 2016; 17(7):889-94. PubMed ID: 26918556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men.
    Aoki K; Kato H; Terauchi Y
    Endocr J; 2007 Dec; 54(6):1009-14. PubMed ID: 18048991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.
    Okada K; Yagyu H; Kotani K; Yamazaki H; Ozaki K; Takahashi M; Nagashima S; Osuga J; Ishibashi S
    Endocr J; 2013; 60(7):913-22. PubMed ID: 23574730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients.
    Aoki K; Nakajima S; Nezu U; Shinoda K; Terauchi Y
    Diabetes Obes Metab; 2008 Sep; 10(10):970-2. PubMed ID: 18721256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study.
    Warnholtz A; Wild P; Ostad MA; Elsner V; Stieber F; Schinzel R; Walter U; Peetz D; Lackner K; Blankenberg S; Munzel T
    Atherosclerosis; 2009 May; 204(1):216-21. PubMed ID: 18822413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
    Johnston PS; Feig PU; Coniff RF; Krol A; Kelley DE; Mooradian AD
    Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.
    Schnack C; Prager RJ; Winkler J; Klauser RM; Schneider BG; Schernthaner G
    Diabetes Care; 1989 Sep; 12(8):537-43. PubMed ID: 2673693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
    Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
    Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office].
    Fehmann HC
    Fortschr Med Orig; 2001 Jul; 119 Suppl 2():55-61. PubMed ID: 15704357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
    Scott LJ; Spencer CM
    Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
    Heinz G; Komjati M; Korn A; Waldhäusl W
    Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML; Tollefsen AT; van Heusden FH; Hoenderdos EB; Jonker JJ; van der Veen EA
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
    Narita T; Yokoyama H; Yamashita R; Sato T; Hosoba M; Morii T; Fujita H; Tsukiyama K; Yamada Y
    Diabetes Obes Metab; 2012 Mar; 14(3):283-7. PubMed ID: 22051162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
    Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
    Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus.
    Su Y; Liu XM; Sun YM; Wang YY; Luan Y; Wu Y
    Am J Cardiol; 2008 Aug; 102(4):497-8. PubMed ID: 18678313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of endothelin blockade on acute exercise-induced changes in blood flow and endothelial function in type 2 diabetes mellitus.
    Schreuder TH; van Lotringen JH; Hopman MT; Thijssen DH
    Exp Physiol; 2014 Sep; 99(9):1253-64. PubMed ID: 24928953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).
    Goldfine AB; Buck JS; Desouza C; Fonseca V; Chen YD; Shoelson SE; Jablonski KA; Creager MA;
    Diabetes Care; 2013 Dec; 36(12):4132-9. PubMed ID: 24130358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin resistance and endothelial dysfunction in type 2 diabetes patients with or without microalbuminuria.
    Yu Y; Suo L; Yu H; Wang C; Tang H
    Diabetes Res Clin Pract; 2004 Aug; 65(2):95-104. PubMed ID: 15223221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study.
    Shimabukuro M; Higa N; Chinen I; Yamakawa K; Takasu N
    J Clin Endocrinol Metab; 2006 Mar; 91(3):837-42. PubMed ID: 16368744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.